Download - Critical Outcome Investor Presentation - March 2014

Transcript
Page 1: Critical Outcome Investor Presentation - March 2014

Investor Presentation | March 2014

The future of drug discovery has arrived

Reducing development time, cost & risk

Page 2: Critical Outcome Investor Presentation - March 2014

2 TSXV: COT

When used anywhere in this presentation, whether oral or written, the words expects, believes, anticipates, estimates and similar expressions are intended to identify forward-looking statements. Forward-looking statements may include statements addressing future financial and operating results of Critical Outcome Technologies Inc. (COTI).

COTI bases these forward-looking statements on its current expectations about future events. Such statements are subject to risks and uncertainties including, but not limited to, the successful implementation of COTI’s strategic plans, the acceptance of new products, the obsolescence of existing products, the resolution of potential patent issues, competition, changes in economic conditions, and other risks described in COTI’s public documents such as press releases and filings with the Toronto Stock Exchange and the Ontario Securities Commission.

All forward-looking statements are qualified in their entirety by the cautionary statements included in this document and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by forward-looking statements contained in this presentation. These forward-looking statements speak only as of the date of this presentation.

Disclaimer

Page 3: Critical Outcome Investor Presentation - March 2014

3 TSXV: COT

3 TSXV: COT

Critical Outcome Technologies Inc.

3

A bioinformatics and accelerated drug discovery company

Listed on the TSX-V under the symbol COT since 2006

Page 4: Critical Outcome Investor Presentation - March 2014

4 TSXV: COT

Investment highlights

1

2

3

We reduce the time, cost & risk of bringing new drugs to market

Potential cancer breakthrough drug candidate is nearly Phase 1 ready

We have many more revenue opportunities in our pipeline

Page 5: Critical Outcome Investor Presentation - March 2014

5 TSXV: COT

Conventional drug development is a long & expensive process characterized by a high risk of failure

11 – 15 years

$1 billion or more

1 FDA approval 5

Page 6: Critical Outcome Investor Presentation - March 2014

6 TSXV: COT

What we do

Reduce drug discovery, optimization & lead selection by 1.5 to 3 yrs.

Saving significant $$$

Increasing revenue period under patent protection

Page 7: Critical Outcome Investor Presentation - March 2014

7 TSXV: COT

How we do it – CHEMSAS®

7 TSXV: COT

Proprietary, artificial intelligence based drug discovery platform technology

Page 8: Critical Outcome Investor Presentation - March 2014

8 TSXV: COT

Failed attempts occur quickly & cheaply in computer simulations, not the ‘wet lab’

Higher probability of clinical & commercial success

Computational replication of traditional ‘wet lab’ drug discovery process

8

Advantages of CHEMSAS®

TSXV: COT

Page 9: Critical Outcome Investor Presentation - March 2014

9 TSXV: COT

Potential cancer breakthrough

Our lead compound, COTI-2, is effective against cancers with mutations of the p53 gene

Page 10: Critical Outcome Investor Presentation - March 2014

10 TSXV: COT

Why COTI-2 is exciting

> 50% of all human cancers have a p53 mutation (eg. ~ 95% of ovarian cancers)

Mechanism of action confirmed by thought leader Dr. Gordon Mills at MD Anderson Cancer Center (June 2013)

Novel, first-in-class

Strong IP protection in place

Page 11: Critical Outcome Investor Presentation - March 2014

11 TSXV: COT

COTI-2 is (nearly) Phase 1 ready

In final 2-species toxicity studies – completion in first half of 2014

FDA IND filing expected in second half of 2014 (leading to Phase 1 clinical trial)

Pursuing orphan drug and/or breakthrough therapy status

Signed an LOI with a strategic partner, Portage Biotech Inc., for clinical development

Page 12: Critical Outcome Investor Presentation - March 2014

12 TSXV: COT TSXV: COT

COTI-2 = significant revenue potential

Top 5 2012 Phase 1/2 oncology licensing deals disclosed (1):

Upfront payments of approx. $25-$92 million

Milestone payments between $550-$1,100 million

Royalties on net sales

1st half of 2013 (2) – 16 Phase 1 licensing deals with 6 in cancer – avg. upfront $30m

(1) Medius Associates (2) Thomson Reuters

Page 13: Critical Outcome Investor Presentation - March 2014

13 TSXV: COT

Other revenue opportunities

Robust internal pipeline of compounds

- AML, colorectal cancer, small cell lung cancer library, MS, etc.

3 existing R&D collaborations expected to bring in milestone payments beginning late 2014 / 2015

- Western University

- Delmar Chemicals

- Major Pharma Co.

Page 14: Critical Outcome Investor Presentation - March 2014

14 TSXV: COT

14 TSXV: COT

Looking ahead

14

Other CHEMSAS® applications:

CHEMFirm – Small molecule profiling & investment due diligence tool

Drug library profiling – Based on customer identified criteria

Drug repurposing – Finding new purposes for drugs coming off patent

Page 15: Critical Outcome Investor Presentation - March 2014

15 TSXV: COT

15 TSXV: COT

Project ROSALIND

15

Programmable computer simulation of human cancer cell signaling

Better personalized treatment decisions based on genetic profile of one’s cancer

Personalized cancer gene profiling projected to be ~ $35B market by 2018

*

* Markets and Markets (2013)

Page 16: Critical Outcome Investor Presentation - March 2014

16 TSXV: COT

Summary

1

2

3

We reduce the time, cost & risk of bringing new drugs to market

Potential cancer breakthrough drug candidate is nearly Phase 1 ready

We have many more revenue opportunities in our pipeline

Page 17: Critical Outcome Investor Presentation - March 2014

The future of drug discovery has arrived

Reducing development time, cost & risk

Dr. Wayne Danter President & CEO Tel: (519) 858-5157 [email protected]

www.criticaloutcome.com www.facebook.com/criticaloutcome twitter.com/criticaloutcome www.slideshare.net/criticaloutcome